Nisha Pandey

Who Is Eligible To Get Eli Lilly's Experimental Weight Loss Drug Before Approval? Criteria Explained

Eli Lilly has launched an early access program that will allow a limited number of patients with severe obesity to receive its experimental weight loss drug retatrutide before it receives approval. The program is only open to a limited number of eligible patients.

According to the company, adults aged 18 years and older may qualify if they have refractory obesity, meaning they have not achieved adequate weight loss despite receiving the highest approved doses of currently available obesity medications. 

Patients must also have at least two obesity-related health conditions, like type 2 <a href="https://www.healthandme.com/health/diabetes">diabetes</a>, cardiovascular disease, or obstructive sleep apnea.

They must also be patients who were unable to enroll in an ongoing clinical trial related to retatrutide or a similar investigational medicine. 

The expanded access, also known as a 'compassionate use' program, is intended for patients with serious medical conditions who have exhausted approved or existing treatment options. 

"<a href="https://www.healthandme.com/health-news/the-next-ozempic-new-4-in-1-weight-loss-drug-could-treat-obesity-diabetes-cancer-and-heart-diseases-article-152648861" data-type="tilCustomLink">Retatrutide </a> is currently an investigational medicine and has not yet been approved by regulatory authorities," Eli Lilly said, adding that the drug should only be accessed through authorised clinical trials or its expanded access program.

Also read: <a href="https://www.healthandme.com/health-wellness/uk-woman-spends-4000-on-wegovy-mounjaro-but-loses-less-than-14-pounds-in-15-months-article-155214674" data-type="tilCustomLink">UK Woman Spends £4,000 On Wegovy, Mounjaro, But Loses Less Than 14 Pounds In 15 Months</a>

Retatrutide is one of <a href="https://www.healthandme.com/health-news/retatrutide-warning-experts-flag-rise-of-fake-weight-loss-jabs-being-sold-online-article-153236293" data-type="tilCustomLink">Eli Lilly's</a> next-generation obesity treatments which is currently under development.

Unlike its currently approved GLP-1 drugs, retatrutide activates three hormone receptors: GLP-1, GIP and glucagon. 

Researchers believe that this triple-action approach could help people lose shed excess weight by reducing appetite as well as increasing their energy expenditure at the same time.

Also read: <a href="https://www.healthandme.com/health-news/johnson-johnson-talc-cancer-row-pharma-giant-to-pay-5-5-billion-to-settle-its-decade-long-controversial-lawsuits-article-155191288" data-type="tilCustomLink">Johnson &amp; Johnson Talc-Cancer Row: Pharma Co To Pay 5.5 Billion To Settle Its Decade-Long Controversial Lawsuits</a>

The drug has piqued significant interests from patients after its late-stage clinical trials showed some of the highest weight loss outcomes seen with an obesity medication. 

In the drug's Phase 3 studies, adults without <a href="https://www.healthandme.com/health/diabetes">diabetes</a> who received the highest dose lost more than 28% of their body weight over 80 weeks.

More recently, Eli Lilly reported that overweight or obese adults living with <a href="https://www.healthandme.com/health-news/did-donald-trump-take-eli-lillys-weight-loss-drug-what-did-white-house-say-article-154744843" data-type="tilCustomLink">type 2 diabetes</a> achieved an average weight loss of 20.8%, further proving the drug's efficacy in different patient groups.

Also read: <a href="https://www.healthandme.com/health-wellness/using-a-compounded-glp-1-drug-heres-what-doctors-want-you-to-know-article-155189876" data-type="tilCustomLink">Using Compounded GLP-1 Drugs? Here's What Doctors Want You to Know</a>

The company plans to submit retatrutide for approval to the US Food and Drug Administration (FDA) in the first quarter of 2027.

The early access announcement comes as Eli Lilly continues to build its portfolio of weight loss medications. 

The company recently released additional Phase 3 data on retatrutide while announcing its plans to obtain regulatory approval in 2027. 

Beyond retatrutide, Lilly is also advancing orforglipron, an investigational <a href="https://www.healthandme.com/health-news/meet-retatrutide-the-unapproved-cousin-of-ozempic-that-supports-weight-loss-differently-article-154187472" data-type="tilCustomLink">oral GLP-1 pill</a>, alongside expanding access to its approved obesity medicine Zepbound.

Oprah Winfrey Gains Weight After Quitting Ozempic

Health experts note that expanded access programs are not the same as regulatory approval. They are meant for select patients who could not participate in the clinical trials and thus have limited treatment options. 

Patients are also advised not to seek investigational medicines through unofficial online sellers or unregulated sources, as retatrutide has not yet been approved by the <a href="https://www.healthandme.com/health-news/why-has-fssai-banned-the-sale-of-dabur-indias-ghee-honey-other-products-article-155249148" data-type="tilCustomLink">FDA</a>.

The drug's safety and quality can only be ensured through authorised clinical studies or Eli Lilly's official expanded access program.

Health Conditions A-Z

health

who-is-eligible-to-get-eli-lillys-experimental-weight-loss-drug-before-approval-criteria-explained

Eli Lilly

Eli Lilly weight loss drug

Retatrutide

glp 1 drugs

type 2 diabetes

Diabetes

eli lilly experimental weight loss drugs

ebola-outbreak-moderna-begins-first-human-trial-of-bundibugyo-vaccine-as-cases-rise-to-3748

Ebola Outbreak: Moderna Begins First Human Trial Of Bundibugyo Vaccine As Cases Rise to 3,748

new-experimental-drugs-could-help-prevent-cancer-from-returning-study

New Experimental Drugs Show Promise In Targeting Tumour Dormancy & Preventing Cancer From Returning

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Eli Lilly has launched an early access program that will allow a limited number of patients with severe obesity to receive its experimental weight loss drug retatrutide before it receives approval. The program is only open to a limited number of eligible patients. According to the company, adults aged 18 years and older may qualify if they have refractory obesity, meaning they have not achieved adequate weight loss despite receiving the highest approved doses of currently available obesity medications. Patients must also have at least two obesity-related health conditions, like type 2 diabetes, cardiovascular disease, or obstructive sleep apnea.They must also be patients who were unable to enroll in an ongoing clinical trial related to retatrutide or a similar investigational medicine. The expanded access, also known as a 'compassionate use' program, is intended for patients with serious medical conditions who have exhausted approved or existing treatment options. "Retatrutide  is currently an investigational medicine and has not yet been approved by regulatory authorities," Eli Lilly said, adding that the drug should only be accessed through authorised clinical trials or its expanded access program.Also read: UK Woman Spends £4,000 On Wegovy, Mounjaro, But Loses Less Than 14 Pounds In 15 Months What Is Retatrutide? Retatrutide is one of Eli Lilly's next-generation obesity treatments which is currently under development. Unlike its currently approved GLP-1 drugs, retatrutide activates three hormone receptors: GLP-1, GIP and glucagon. Researchers believe that this triple-action approach could help people lose shed excess weight by reducing appetite as well as increasing their energy expenditure at the same time.Also read: Johnson & Johnson Talc-Cancer Row: Pharma Co To Pay 5.5 Billion To Settle Its Decade-Long Controversial LawsuitsPromising Results  The drug has piqued significant interests from patients after its late-stage clinical trials showed some of the highest weight loss outcomes seen with an obesity medication. In the drug's Phase 3 studies, adults without diabetes who received the highest dose lost more than 28% of their body weight over 80 weeks. More recently, Eli Lilly reported that overweight or obese adults living with type 2 diabetes achieved an average weight loss of 20.8%, further proving the drug's efficacy in different patient groups.Also read: Using Compounded GLP-1 Drugs? Here's What Doctors Want You to Know The company plans to submit retatrutide for approval to the US Food and Drug Administration (FDA) in the first quarter of 2027.The early access announcement comes as Eli Lilly continues to build its portfolio of weight loss medications. The company recently released additional Phase 3 data on retatrutide while announcing its plans to obtain regulatory approval in 2027. Beyond retatrutide, Lilly is also advancing orforglipron, an investigational oral GLP-1 pill, alongside expanding access to its approved obesity medicine Zepbound. What Patients Should Know       Health experts note that expanded access programs are not the same as regulatory approval. They are meant for select patients who could not participate in the clinical trials and thus have limited treatment options. Patients are also advised not to seek investigational medicines through unofficial online sellers or unregulated sources, as retatrutide has not yet been approved by the FDA. The drug's safety and quality can only be ensured through authorised clinical studies or Eli Lilly's official expanded access program.

who is eligible to get eli lilly's experimental weight loss drug before approval? criteria explained

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Who Is Eligible To Get Eli Lilly's Experimental Weight Loss Drug Before Approval? Criteria Explained

Ebola Outbreak: Moderna Begins First Human Trial Of Bundibugyo Vaccine As Cases Rise to 3,748

New Experimental Drugs Show Promise In Targeting Tumour Dormancy & Preventing Cancer From Returning

Study Finds A Common Amino Acid May Strengthen The Body's Defence Against Cancer And Viral Infections

Health Conditions A-Z

Who Is Eligible To Get Eli Lilly's Experimental Weight Loss Drug Before Approval? Criteria Explained

Ebola Outbreak: Moderna Begins First Human Trial Of Bundibugyo Vaccine As Cases Rise to 3,748

New Experimental Drugs Show Promise In Targeting Tumour Dormancy & Preventing Cancer From Returning